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Objective. Our purpose was to measure cardiologists' level of 
adherence to guidelines for long-term use of beta-adrenergic 
blocker therapy after acute myocardial infarction. 
Background. Beta-blocker therapy after acute myocardial in- 
farction has been shown to reduce the incidence of reinfarction 
and associated mortality. To learn about cardiologists' use of this 
therapy after hospital discharge and their level of adherence to 
American College of Cardiology guidelines, we analyzed insurance 
claims from 17 network-model health plans located throughout 
the United States. 
Methods. The study group included 150 cardiologists who had 
contracts with one of the health plans and their 280 patients who 
were plan members (excluding Medicare enrollees) and received 
inpatient treatment for acute myocardial infarction that did not 
include revascularization during 1992. These patients accounted 
for 307 separate hospital admissions. Insurance claims were used 
to measure beta-blocker usage and to identify possible contrain- 
dications. 
Results. Forty-three percent of the cases (131 of 307) involved 
apparent deviations from the guidelines: 11% of cases (35 of 307) 
involved possible errors of commission (beta-blocker given in the 
presence of a contraindication) and 31% (96 of 307) errors of 
omission (beta-blocker not given in the absence of a contraindi- 
cation). Of the 185 patients who were eligible for the therapy (no 
contraindications), only 48% (89 of 185) were treated. 
Conclusions. Cardiologists currently exhibit a low level of 
compliance with their specialty's guidelines for postinfarction 
beta-blockade. Slightly fewer than 50% of the study patients who 
were eligible for treatment actually received a beta-blocker after 
hospital discharge. This result, combined with the drug's known 
level of effectiveness in preventing recurrent myocardial infarc- 
tion, suggests that increased use could avert -1,900 deaths 
annually nationwide. 
(J Am CoU Cardiol 1995;26:1432-6) 
Beta-adrenergic blocker therapy after acute myocardial infarc- 
tion has been shown to reduce the incidence of reinfarction 
and associated mortality. Persuasive vidence of these benefi- 
cial effects has been reported since the mid-1980s (1). On the 
basis of this evidence, the American College of Cardiology 
recommends beta-blockade routinely for secondary prevention 
in the absence of specific contraindications (2). 
To learn about cardiologists' long-term use of beta-blocker 
therapy after myocardial infarction and their level of adher- 
ence to their specialty's guidelines, we analyzed insurance 
claims in a group of network-model health plans. The decision 
to examine use of this therapy was based on several consider- 
ations: 1) Postinfarction beta-blocker therapy is an important 
quality of care issue because optimizing use of this therapy 
could have a substantial impact on morbidity and mortality in 
the general population (3). 2) There is little controversy about 
the therapy because its benefit has been well established (1,2); 
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it has few serious ide effects (4); it is relatively inexpensive; 
and recommendations for its use are contained in the practice 
guidelines of a nationally recognized specialty society. 3) Data 
needed to identify the study group and analyze drug utilization 
can be obtained from insurance claims. 
Methods 
Study group. This study was carried out in a group of 
network-model health plans affiliated with a large managed 
care organization. Network-model health plans--sometimes 
called independent practice associations--contract with physi- 
cian groups to provide health care services to plan members. 
These plans typically pay network physicians on a discounted 
fee-for-service basis and allow patients open access to the 
physicians, who work out of their own offices. 
Several of the affiliate health plans consist of two or more 
divisions, each of which has a distinct membership and benefit 
structure. For convenience, these divisions are referred to in 
this report as "health plans," although technically they are 
divisions of health plans. 
The study group included all cardiologists who had con- 
tracts with one of 17 health plans and their patients (excluding 
Medicare) who were plan members and received inpatient 
treatment for acute myocardial infarction that did not include 
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revascularization between January 1 and December 31, 1992. 
Medicare enrollees were excluded because the absence of a 
pharmacy benefit in this population precluded claims-based 
analysis of their beta-blocker usage. A few affiliate plans were 
excluded because their administrative data systems did not 
generate sufficiently detailed and complete data for the study. 
The 17 study plans serve urban and suburban populations in 10 
states: Rhode Island, North Carolina, South Carolina, Geor- 
gia, Michigan, Minnesota, Illinois, Missouri, Nebraska and 
Utah. Cardiologists in solo practices as well as group practices 
are represented in the study, and their affiliations include 
community and university hospitals. The health plans had a 
combined enrollment of 955,000 when the study began, with 
individual plan enrollments ranging from 3,000 to 340,000. 
Data. Administrative data were used to identify the study 
group as well as to determine which postinfarction patients 
were eligible for beta-blocker therapy and which patients 
actually received it. These data are maintained in a centrally 
housed system of linked administrative data bases. An enroll- 
ment data base includes member demographics and dates of 
enrollment in the health plan. Each plan member has a unique 
identifier that permits the attribution of services to the correct 
individual (different family members have separate identifiers). 
These identifiers also permit he linking of claims from hospi- 
tals, physicians and pharmacies to allow longitudinal analysis 
of plan members' medical care and use of prescription drugs. 
A claims data base contains claims for services provided to 
plan members. These claims must be submitted to the health 
plan by providers (physicians, facilities or pharmacies) to 
receive payment. Claims are submitted from all sites (e.g., 
inpatient, hospital outpatient, emergency room, physician's 
office, surgery center, pharmacy) for virtually all services. 
Coding of claims conforms to insurance industry standards, 
including use of the International Classification of Diseases 
(ICD-9-CM) (5) for the coding of diagnoses and Physicians' 
Current Procedural Terminology (CPT) (6) or ICD-9-CM for 
the coding of procedures. Claims for pharmacy services are 
submitted electronically at the time a prescription is filled. 
Each pharmacy claim specifies the type of drug, dosage, 
amount dispensed and number of days' supply. 
Identification of study group. Cardiologists. To analyze 
medical care provided by cardiologists, it was necessary to 
establish an operational definition of a "cardiologist." A plan 
provider was designated as a cardiologist if the majority of the 
services provided to plan members by that individual involved 
evaluation or treatment of cardiac problems, and the provider 
was not a surgeon. This definition led to the inclusion of 
physicians who practice predominately cardiology and to the 
exclusion of other subspecialists or primary care physicians 
who may treat some cardiac problems but whose practices are 
not devoted primarily to cardiology. It was judged that this 
definition, based on actual practice patterns, would produce a 
more meaningful peer group than a definition that relied on a 
physician's elf-designation as a cardiologist or a criterion 
based on credentialing, such as board certification in cardiol- 
ogy. 
Table 1. ICD-9-CM Codes Classified as "Cardiac" 
402-402.91 
404-404.9 
410-410.9 
411-411.8 
412 
413-413.9 
414-414.9 
415-415.1 
416-416.9 
420 -420.99 
421-421.9 
422-422.9 
423-423.9 
424-424.99 
425-425.9 
426-426.9 
427-427.9 
428-428.9 
429-429.9 
745-745.9 
746-746.9 
Hypertensive heart disease 
Hypertensive heart and renal disease 
Acute myocardial infarction 
Other acute and subacute forms of ischemic heart disease 
Old myocardial infarction 
Angina pectoris 
Other forms of chronic ischemic heart disease 
Acute pulmonary heart disease 
Chronic pulmonary heart disease 
Acute pericarditis 
Acute and subacute ndocarditis 
Acute myocarditis 
Other diseases of pericardium 
Other diseases of endocardium 
Cardiomyopathy 
Conduction disorders 
Cardiac arrhythmias 
Heart failure 
Ill-defined descriptions and complications of heart disease 
Bulbus cordis anomalies and anomalies of cardiac septal closure 
Other congenital anomalies of heart 
To identify plan cardiologists, each claim for a service 
submitted by a plan physician during 1992 was classified as a 
"cardiac" or "noncardiac" claim. A claim was considered 
cardiac if a cardiac problem was listed as the principal diag- 
nosis (Table 1). If at least 50% of a given physician's claims 
were classified "cardiac," and at least 30 services (separate 
procedure codes) were submitted and paid during the year, 
that physician was designated a cardiologist and included in the 
physician study group. The latter criterion excluded physicians 
with limited practices that would not generate nough data for 
analysis purposes. 
Postinfarction patients. The patient study group included 
plan members who had been under the care of a plan 
cardiologist at some time during the year and who received 
inpatient reatment for acute myocardial infarction that did 
not include revascularization. A member was considered to 
have been under a cardiologist's care if the member had at 
least one office visit to a plan cardiologist resulting in the 
payment of one or more cardiac laims. 
Analysis. Postinfarction patients were identified from 
claims submitted by hospitals that listed an ICD-9-CM dis- 
charge diagnosis in the range 410 to 410.9. Claims for angio- 
plasties (ICD-9-CM procedure codes 36.01 to 36.09) and 
coronary bypass operations (codes 36.10 to 36.16) distin- 
guished which of these patients had undergone revasculariza- 
tion during the hospital period and were therefore xcluded. 
Claims with a principal or secondary discharge diagnosis listed 
in Table 2 signaled the presence of a contraindication to 
beta-blocker usage. Office visits were identified from claims 
submitted by cardiologists with CPT codes designating an 
office visit (90000 to 90653, 99201 to 99353) or specifying a 
cardiac procedure (33010 to 33015, 36100 to 36299, 75500 to 
75519, 92950 to 92990, 93014 to 93660) that was performed in 
an office setting. Finally, claims submitted by pharmacies were 
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Table 2. ICD-9-CM Codes Denoting Contraindications to 
Beta-Blocker Usage* 
250-250.9 Diabetes mellitust 
426.10-426.13 Atrioventricular block, other and unspecified 
426.6 Other heart block 
426.9 Conduction disorder, unspecified 
427.8-427.89 Other specified cardiac arrhythmias 
428-428.9 Heart failure 
493-493.9 Asthmat 
*Adapted from reference 2. tDiagnosis designated as a "relative" contrain- 
dication in the American College of Cardiology guidelines. 
examined to determine which myocardial infarction patients 
received a prescription for a beta-blocker within 90 days of 
discharge. 
These data made it possible to determine whether the 
American College of Cardiology guidelines appear to have 
been followed for each patient. Use of a beta-blocker when 
contraindicated or failure to use the drug in the absence of a 
contraindication represent two possible quality of care prob- 
lems. Patients with revascularization were excluded from the 
analysis because the guidelines do not offer clear-cut recom- 
mendations for treatment in this subgroup (2). 
Resu l ts  
There were 280 patients in the 17 health plans who had 
been under the care of a plan cardiologist during the year and 
who received inpatient reatment for acute myocardial infarc- 
tion that did not include revascularization. One hundred fifty 
cardiologists were involved in the care of these patients, who 
generated a total of 307 separate hospital admissions. 
Each case (hospital discharge) fell into one of four catego- 
ries according to postdischarge b ta-blocker usage and pres- 
ence or absence of contraindications (Table 3). For example, 
31% of patients (96 of 307) did not receive a beta-blocker 
within 90 days of discharge and did not have a contraindication 
(Table 3, far right column). The percent of patients in this 
category varied greatly from plan to plan, but these percent- 
ages were based on a small number of patients except in the 
larger plans. Only the four largest plans (Table 3, A to D) had 
>20 patients meeting the study's inclusion criteria. At these 
four plans, 18% to 31% of patients were within the given 
category. For the smaller plans, the percentages shown in 
Table 3 cannot be considered statistically reliable. 
Boldface entries in Table 3 indicate apparent deviations 
from the American College of Cardiology guidelines. For 
example, 124 patients received beta-blocker therapy after 
hospital discharge, of whom 35 had comorbidities that are 
considered contraindications (definite or "relative") (Table 2). 
Of the 183 patients who did not receive abeta-blocker, 87 had 
a contraindication (i.e., 96 patients had no apparent contrain- 
dication that would justify withholding beta-blocker therapy). 
It follows that 43% of cases ([35 + 96] of 307) involved 
possible errors of commission or omission related to beta- 
blocker therapy. 
Of the patients who were eligible for beta-blockade (no 
contraindications), 48% (89 of [89 + 96]) were treated. In the 
Table 3. Postdischarge B ta-Blocker Usage and Evidence of Contraindications i  Patients With Acute Myocardial Infarction* 
Beta-Blockert No Beta-Blockert 
No. of No No 
No. of No. of Hospital Contraindication~t Contraindication Contraindication Contraindication$ 
Plan Enrollment Cardiologists Pts Admissions [no. (%) of pts] [no. (%) of pts] [no. (%) of pts] [no. (%) of pts] 
A 340,000 52 115 125 10 (8) 39 (31) 37 (30) 39 (31) 
B 125,000 23 52 61 11 (18) 22 (36) 17 (28) 11 (18) 
C 85,000 9 25 27 4 (15) 7 (26) 8 (30) 8 O0) 
D 76,000 14 27 29 4 (14) 10 (34) 6 (21) 9 (31) 
E 66,000 7 8 10 2 (20) 0 (0) 4 (40) 4 (40) 
F 60,000 5 6 6 1 (17) 2 (33) 0 (0) 3 (50) 
G 46,000 6 7 7 1 (14) 1 (14) 3 (43) 2 (29) 
H 38,000 4 5 5 0 (0) 1 (20) 2 (40) 2 (40) 
I 25,000 4 6 7 1 (14) 1 (14) 2 (29) 3 (43) 
J 23,000 4 4 4 0 (0) 2 (50) 1 (25) 1 (25) 
K 18,000 4 6 6 0 (0) 1 (17) 1 (17) 4 (67) 
L 17,000 2 2 2 0 (0) 1 (50) 0 (0) 1 (50) 
M 11,0130 2 2 2 0 (0) 0 (0) 1 (50) 1 (50) 
N 9,000 10 10 10 1 (10) 1 (10) 3 (30) 5 (50) 
0 8,000 2 2 2 0 (0) 1 (50) 1 (50) 0 (0) 
P 5,000 2 2 2 0 (0) 0 (0) 0 (0) 2 (100) 
O 3,000 1 1 2 0 (0) 0 (0) 1 (50) 1 (so) 
Total 955,000 150 280 307 35 (11) 89 (29) 87 (28) 96 (31) 
*With a discharge diagnosis of acute myocardial infarction, excluding patients who underwent revascularization, tWithin 90 days of discharge. ~Boldface indicates 
apparent errors of commission (beta-blocker given in the presence of a contraindication) oromission (beta-blocker not given in the absence of a contraindieation). Pts = 
patients. 
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four large plans with enough patients to yield reliable stimates 
of treatment rates, the percentages were 47%, 50%, 53% and 
67% at plans C, A, D and B, respectively. Even in the best 
performing of the four plans, therefore, one-third of eligible 
patients were untreated. Assuming that these results are 
generalizable, we may conclude that cardiologists currently 
exhibit a low level of compliance with their own specialty 
society's guidelines. 
Discuss ion  
Increased use of beta-blockade after myocardial infarction 
could avert 1,900 deaths annually in the United States, accord- 
ing to a recent epidemiologic analysis by Siu et al. (3). This 
estimate assumes that 50% of postinfarction patients are 
eligible for treatment (no contraindications), that 40% of 
eligible patients are currently treated and that this last per- 
centage could be increased to 75% through quality improve- 
ment efforts. Deaths would be averted under this scenario 
because an additional 17% of all postinfarction patients (50% 
[75% - 40%]) would receive treatment. In our study group, 
60% of patients (185 of 307) were eligible for treatment, and 
48% of eligible patients (89 of 185) were treated after dis- 
charge from the hospital. If these results are substituted for the 
estimates of Siu et al. (3), an additional 16% of postinfarction 
patients (60% [75% - 48%]) would receive treatment if the 
target of 75 % compliance were achieved. In other words, if the 
pattern of practice observed in the present study is typical of 
practices nationwide, then the potential impact of improved 
beta-blocker usage would differ only slightly from the Siu et al. 
projection of 1,900 lives saved. 
Generalizability. One must be cautious about generalizing 
results from a group of nonrandomly selected health plans. At 
the same time, there are several reasons for believing that the 
cardiologists tudied here are reasonably representative of
cardiologists in private practice nationwide: 1) The study 
included a large number of geographically diverse health plans. 
2) These network-model health plans incorporate the most 
common type of practice arrangement found in the United 
States, namely, physicians practicing in their own offices and 
receiving payment for individual services provided. 3) Physi- 
cians in the study treated patients covered by various insurance 
policies and health plans. Although the practice patterns 
reported here are based on patients who were enrolled in 
specific health plans, there is little reason to believe that these 
physicians would treat their other insured patients differently. 
Previous studies of beta-blocker usage after myocardial 
infarction have focused on patterns of treatment during the 
hospital stay. These studies, from Australia (7), Israel (8), 
Canada (9) and the United States (10,11), documented sub- 
stantial underuse of beta-blockade in the hospital, especially 
among the elderly (9,10). The present study indicates that this 
pattern of undertreatment during the hospital period persists 
after discharge, depriving many patients of a potentially ben- 
eficial preventive therapy. 
Measurement biases. It is important to recognize potential 
sources of measurement bias when using claims data to 
determine compliance with guidelines. Both positive biases 
(measured value exceeds true value) and negative biases 
(measured value falls below true value) must be considered. 
A bias, either positive or negative, may occur because the 
American College of Cardiology guidelines characterize cer- 
tain contraindications as "relative." For a patient with a 
relative contraindication, the physician is expected to consider 
whether the risk of an adverse reaction to therapy would, in 
that patient, outweigh the potential benefit. In our claims- 
based analysis, any contraindication, i cluding a relative con- 
traindication, was considered justification for withholding 
beta-blocker therapy, although some patients with relative 
contraindications might be considered eligible based on clini- 
cal judgment. The true percentage of eligible patients treated 
could therefore be either higher or lower than the percentage 
based on the claims analysis, depending on how many addi- 
tional eligible patients received a beta-blocker. 
Patients were not included in the present study if they 
received all of their cardiac are from primary care physicians. 
Because cardiologists are most familiar with their specialty's 
guidelines (14), their level of adherence to these guidelines 
probably exceeds the average level for all physicians treating 
myocardial infarction patients. In other words, the study 
identified significant quality of care problems in spite of having 
examined putatively best practices. 
There are several potential sources of negative bias. 
1. According to the guidelines, postinfarction beta- 
blockade is optional in patients with a small infarction who 
have no evidence of continuing ischemia. In other words, 
eligibility for treatment is not the same thing as necessity for 
treatment. Because claims do not contain detailed diagnostic 
information indicative of infarction size or signs and symptoms 
at discharge from the hospital, claims data cannot identify this 
subset of patients who may not require a beta-blocker. If some 
eligible patients do not require therapy, then the percentage of
eligible patients treated will produce a negatively biased quality- 
of-care indicator. 
2. Patients who died in the hospital cannot be reliably 
identified from claims data. Consequently, these patients are 
included in the study group, although their failure to receive 
beta-blocker therapy subsequent to their hospital stay obvi- 
ously does not indicate a quality-of-care problem. 
3. Pharmacy claims are generated when prescriptions are 
filled, not when they are written. Because patients do not 
always fill their prescriptions, claims data may understate the 
number of beta-blocker p escriptions written. Although the pa- 
tient receives no benefit from an unfilled prescription, the 
cardiologist in such a case should probably be credited with 
having adhered to the guidelines. 
4. A prescription may fail to generate a claim if a patient 
pays the full price out of pocket because the pharmacy has no 
reason to submit a claim. This circumstance occurs when the 
price of a prescription falls below the patient's copayment, 
which is $6 to $10/prescription, depending on the benefit 
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contract. Some prescriptions for propranolol or for small doses 
of atenolol may have fallen into this category and have been 
missed. 
These four sources of bias all operate in the same direction, 
theoretically producing a measured level of adherence below 
the true level. Nevertheless, the study yielded a sufficiently low 
percentage of eligible patients treated that even assuming a 
true level 25% higher than that observed (i.e., 60 vs. 48%) 
would still leave much room for improvement. 
Because previous investigators (12,13) have shown that 
physicians are slow to adopt clinical practice guidelines, the 
finding that cardiologists do not always adhere to the beta- 
blocker guideline is not particularly surprising. However, such 
a low level of adherence was not anticipated. It was substan- 
tially lower than might have been expected on the basis of a 
recent survey (14) of physicians' knowledge and practices. In 
that survey, 77.5% of cardiologists aid that they would be very 
likely to prescribe long-term beta-blocker therapy after acute 
myocardial infarction. 
Physicians today may deviate from certain recommenda- 
tions of the American College of Cardiology on the basis of 
evidence published after the guidelines were written. For 
example, certain recent studies (15,16) suggest hat postinfarc- 
tion patients with heart failure should receive beta-blocker 
therapy. Nevertheless, because the present study analyzed 
prescribing practices prevalent in 1992, it is appropriate to 
evaluate those practices relative to guidelines that were current 
at that time. 
Parallel evidence. A recent pilot study (17) of treatment 
patterns in Medicare patients with acute myocardial infarction, 
sponsored by the Health Care Financing Administration, 
provides parallel evidence consistent with our findings. That 
study was carried out by the Connecticut Peer Review Orga- 
nization using data abstracted from the hospital charts of 300 
postinfarction patients discharged from six Connecticut hospi- 
tals between October 1989 and September 1991. In the group 
of patients who were alive at discharge and did not have a 
contraindication to beta-blocker therapy, 41% received a 
prescription at the time of discharge. The similarity of this 
result to our 48% rate of treatment suggests that our claims- 
based analysis did not produce markedly biased results. 
Conclusions. In the present study of 150 cardiologists 
practicing in locations throughout he United States, slightly 
fewer than 50% of their patients who were eligible for beta- 
blocker therapy after acute myocardial infarction actually 
received the drug after discharge from the hospital. Because 
this practice pattern is probably typical of cardiologists' prac- 
tices nationwide, quality improvement initiatives to increase 
beta-blocker usage could prevent a substantial number of 
repeat infarctions and associated eaths. 
We are indebted to Loretta Carr, BS and John A. Kohner, MBA for their 
assistance with the analysis and to John E. Brush, Jr., MD for helpful comments 
on an early draft of the manuscript. 
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